ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING

Show other versions (1)

Objectives. To estimate the relationship of proprotein convertase subtilisin/kexin type 9 (PCSK9) level with blood pressure (BP) and smoking in a population of young males in Novosibirsk.Material and methods. The group was formed by the method of random numbers from the population sample of Novosib...

Full description

Bibliographic Details
Main Authors:	K. S. Benimetskaya, M. P. Yachmeneva, S. V. Astrakov, L. V. Shcherbakova, D. V. Denisova, Yu. I. Ragino, M. I. Voevoda
Format:	Article
Language:	Russian
Published:	Scientific Research Institute, Ochapovsky Regional Clinical Hospital no. 1 2019-03-01
Series:	Инновационная медицина Кубани
Subjects:	proprotein convertase subtilisin/kexin type 9 pcsk9 population hypertension smoking
Online Access:	https://www.innovmedkub.ru/jour/article/view/151

Similar Items

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9
by: K. S. Astrakova, et al.
Published: (2015-06-01)

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022-03-01)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01)

ASSOCIATION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN FAMILIAL HYPERCHOLESTEROLEMIA
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
by: Ga Eun Lee, et al.
Published: (2021-01-01)

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
by: Maria Pia Adorni, et al.
Published: (2019-05-01)

Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet’s disease
by: Rabia Aydogan Baykara, et al.
Published: (2022-07-01)

Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes
by: V.A. Serhiyenko, et al.
Published: (2023-03-01)

RETRACTED ARTICLE: Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
by: Khursheed Muzammil, et al.
Published: (2024-03-01)

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
by: Natalie Schellack, et al.
Published: (2016-01-01)

The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in macrophage activation: a focus on its LDL receptor-independent mechanisms
by: Shunsuke Katsuki, et al.
Published: (2024-08-01)

THE INVOLVEMENT PROPROTEIN CONVERTASE SUBTILISIN/KEXIN OF TYPE 9 IN THE PATHOGENESIS OF ATHEROSCLEROSIS (LITERATURE REVIEW)
by: A. M. Chaulin
Published: (2020-03-01)

New groups of hypolipidemic drugs based on inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). Part 1
by: Aleksey M. Chaulin, et al.
Published: (2021-03-01)

Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention
by: Michelangelo Rottura, et al.
Published: (2025-03-01)

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
by: Thomas S. Metkus, et al.
Published: (2022-06-01)

Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians
by: Terrence L Trentman, et al.
Published: (2016-01-01)

Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells
by: Ting‐Hsing Chao, et al.
Published: (2016-05-01)

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors
by: Je-Wen Liou, et al.
Published: (2024-09-01)

Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia
by: Łukasz Wołowiec, et al.
Published: (2016-07-01)

Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia
by: Łukasz Wołowiec, et al.
Published: (2016-07-01)

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis
by: Yousuf Zafar, et al.
Published: (2020-01-01)

Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors
by: Ryosuke Tani, et al.
Published: (2024-02-01)

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels Predict Future Cardiovascular Event Risks in Hemodialyzed Black African Patients
by: François-Pantaléon Musungayi Kajingulu, et al.
Published: (2021-07-01)

Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia
by: Hongyan Jiang, et al.
Published: (2024-12-01)

Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund
by: Beata Bobrowska, et al.
Published: (2022-08-01)

Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study
by: Isabela Bensenor, et al.
Published: (2021-09-01)

Effects of Serum Estradiol on Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Lipid Profiles in Women Undergoing In Vitro Fertilization
by: Anna Papanikolaou, et al.
Published: (2024-01-01)

Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis
by: Jiahui Liu, et al.
Published: (2021-11-01)

Analysis of Influencing Factors of Plasma Proprotein Convertase Subtilisin/Kexin Type 9 in Patients with Acute Myocardial Infarction
by: JIA Jia, LIU Jiahui, JI Wenjun, ZHENG Bo, WANG Xingang, FAN Fangfang, LI Yin, ZHANG Long, ZHANG Yan
Published: (2024-12-01)

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study
by: Jie Shi, et al.
Published: (2021-05-01)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
by: Payal Kohli, et al.
Published: (2016-05-01)

Circulating Proprotein Convertase Subtilisin/Kexin type 9 level independently predicts incident cardiovascular events and all-cause mortality in hemodialysis black Africans patients
by: François-Pantaléon Musungayi Kajingulu, et al.
Published: (2022-03-01)

Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study
by: Massimiliano Ruscica, et al.
Published: (2017-05-01)

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
by: Yue-Wei Qian, et al.
Published: (2007-07-01)

Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center
by: Chia-Ling Tsai, et al.
Published: (2022-09-01)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
by: Constantine E Kosmas, et al.
Published: (2017-11-01)

ASSOCIATION OF POLYMORPHISM IN PCSK9 GENE WITH LIPID PR OFILE IN RUSSIAN POPULATION
by: K. S. Astrakova, et al.
Published: (2016-06-01)

The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin–Kexin Type 7 (<i>PCSK7</i>) Gene Are Associated with Acute Coronary Syndrome and with Plasma Concentrations of HDL-Cholesterol and Triglycerides
by: Gilberto Vargas-Alarcón, et al.
Published: (2021-06-01)